Evidence map›Paper›PMID 30691170›Full record

ArticleMolecules (Basel, Switzerland)2019

Interdisciplinary Tasks in the Cyclotron Production of Radiometals for Medical Applications. The Case of

Alessandra Boschi, Petra Martini, Valentina Costa, Antonella Pagnoni, Licia Uccelli

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Towards a dry separation method of radioscandium from bulk amounts of titanium.Journal of radioanalytical and nuclear chemistry · 2025
    Article
  3. Article
  4. Article
  5. Recent Advances inInternational journal of molecular sciences · 2023
    Review
  6. Article
  7. Review
  8. Cyclotron-based production ofEJNMMI radiopharmacy and chemistry · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alessandra BoschiDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Luigi Borsari, 46-44121 Ferrara, Italy. alessandra.boschi@unife.it.ORCID 0000-0002-6382-1944
Petra MartiniDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Luigi Borsari, 46-44121 Ferrara, Italy. petra.martini@unife.it.ORCID 0000-0002-4059-4814
Valentina CostaDepartment of Chemical and Pharmaceutical Sciences, University of Ferrara, Via Luigi Borsari, 46-44121 Ferrara, Italy. valentina.costa@unife.it.ORCID 0000-0001-8188-831X
Antonella PagnoniDepartment of Chemical and Pharmaceutical Sciences, University of Ferrara, Via Luigi Borsari, 46-44121 Ferrara, Italy. antonella.pagnoni@unife.it.
Licia UccelliDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Luigi Borsari, 46-44121 Ferrara, Italy. licia.uccelli@unife.it.
University of Ferrara · ITIstituto Nazionale di Fisica Nucleare · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The growing number of cyclotrons of different sizes installed in the territory has given a strong impulse to the production of conventional and emerging radionuclides for medical applications. In particular, the great advantage of using medical cyclotrons is the possibility to produce on-site, when needed (on-demand), with medical radionuclides of interest encouraging the personalized medicine approach. Radiometals satisfy the ideal characteristics that radionuclides should have for routine employment in nuclear medicine, especially since they have a robust chemistry suitable to synthetize stable in vivo radiopharmaceuticals with high radiochemical yields. In this letter several interdisciplinary aspects involved in the radiometals cyclotron production cycle are summarized focusing the attention on cyclotron production facilities, target material, and chemical processing available for medical applications. As an example, the current status and recent development in the production of the theranostic radionuclide scandium-47 have been reported.

Indexed as

CyclotronsRadioisotopesRadiopharmaceuticalsScandiumHumansNuclear MedicineRadionuclide ImagingRadioisotopesRadiopharmaceuticalsScandiumScandium-47automationcyclotronradiochemical separationradiometalstarget

Identifiers

PMID30691170
PMCPMC6385051
OpenAlexW2913754566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.